Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients.
OBJECTIVE
To determine the prevalence of the most often tested autoantibodies in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.


METHODS
We identified 90 patients seen in our unit between June 2002 and June 2009, and diagnosed according to the proposed criteria for SAPHO syndrome. Demographic and clinical data were collected as well as immunological results, including antinuclear, antithyroid peroxydase (TPO), antithyroid globulin (Tg), antigastric parietal cell, antismooth muscle, antimitochondria, and anti-liver-kidney microsome (LKM) antibodies. Anticyclic citrullinated peptide (CCP) antibodies were analyzed in 69 patients, antibodies to soluble extractable nuclear antigens in 43, anti-double-stranded DNA (dsDNA) antibodies in 22 [depending on the type of fluorescence of antinuclear antibody (ANA)], and antiendomysium antibodies in 55.


RESULTS
Autoantibodies were found in 20 patients (22.2%): 14 patients (15.5%) had positive ANA (titer >/= 1/160); among them, 10 (11%) patients never took a lupus-inducing drug. Antithyroid antibodies (anti-TPO and/or anti-Tg antibodies) were found in only 3 patients (3.3%). Three patients (3.3%) were positive for antigastric parietal cell antibodies and 4 (4.4%) were weakly positive for antismooth muscle antibodies. Antimitochondria and LKM antibodies were negative in all 90 patients. Anti-CCP and anti-dsDNA antibodies were negative in the 69 and 22 patients tested, respectively. One out of 43 patients (2.3%) had anti-SSA antibodies. Antiendomysium antibodies were negative in the 55 patients tested.


CONCLUSIONS
Our study indicates an increased prevalence of autoantibodies in SAPHO syndrome, with no specific profile. We failed to confirm the reports of an increased prevalence of antithyroid antibodies. These results tend to support a link between autoimmunity and SAPHO syndrome.
Grosjean
Céline
C
Department of Rheumatology and Department of Immunology, Bichat Teaching Hospital, Paris, France.
Hurtado-Nedelec
Margarita
M
Nicaise-Roland
Pascale
P
Ferreyra-Dillon
Rodrigo
R
Bollet
Caroline
C
Quintin
Emilie
E
Dieude
Philippe
P
Palazzo
Elisabeth
E
Wattiaux
Marie-José
MJ
Kahn
Marcel-Francis
MF
Meyer
Olivier
O
Chollet-Martin
Sylvie
S
Hayem
Gilles
G
D020083:Acquired Hyperostosis Syndrome / Q000097:blood / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology*; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D007453:Iodide Peroxidase / Q000276:immunology; D033862:Iron-Binding Proteins / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000276:immunology; D010295:Parietal Cells, Gastric / Q000276:immunology; D010456:Peptides, Cyclic / Q000276:immunology; D011446:Prospective Studies; D012189:Retrospective Studies; D055815:Young Adult
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D001324:Autoantigens; D033862:Iron-Binding Proteins; D010456:Peptides, Cyclic; C060729:anti-liver kidney microsome antibody; C006606:anti-thyroglobulin; C487763:cyclic citrullinated peptide; D004247:DNA; C056658:TPO protein, human; D007453:Iodide Peroxidase